Literature DB >> 28167549

New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae.

Zackery P Bulman1,2, Michael J Satlin3, Liang Chen4, Barry N Kreiswirth4, Beom Soo Shin5, Thomas J Walsh3, Patricia N Holden1,2, Alan Forrest6, Roger L Nation7, Jian Li7, Brian T Tsuji8,2.   

Abstract

Pharmacodynamics of a polymyxin B, meropenem, and rifampin triple combination were examined against Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) ST258. In time-kill experiments against three KPC-Kp isolates, triple combination generated 8.14, 8.19, and 8.29 log10 CFU/ml reductions within 24 h. In the hollow-fiber infection model, the triple combination caused maximal killing of 5.16 log10 CFU/ml at 78 h and the time required for regrowth was more than doubled versus the 2-drug combinations. Remarkably, combinations with a high single-dose polymyxin B burst plus rifampin preserved KPC-Kp polymyxin susceptibility (MIC240 h = 0.5 mg/liter) versus the same combination with traditionally dosed polymyxin B, where resistance was amplified (MIC240 h = 32 mg/liter).
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  KPC-producing K. pneumoniae; PK/PD; meropenem; polymyxin B; rifampin

Mesh：

Substances：

Year:  2017        PMID： 28167549      PMCID： PMC5365650          DOI： 10.1128/AAC.02023-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  39 in total

1.  In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli.

Authors:  Carl Urban; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

2.  High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.

Authors:  Justin R Lenhard; Jürgen B Bulitta; Terry D Connell; Natalie King-Lyons; Cornelia B Landersdorfer; Soon-Ee Cheah; Visanu Thamlikitkul; Beom Soo Shin; Gauri Rao; Patricia N Holden; Thomas J Walsh; Alan Forrest; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  J Antimicrob Chemother       Date:  2016-09-15       Impact factor: 5.790

3.  Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.

Authors:  Mario Tumbarello; Enrico Maria Trecarichi; Francesco Giuseppe De Rosa; Maddalena Giannella; Daniele Roberto Giacobbe; Matteo Bassetti; Angela Raffaella Losito; Michele Bartoletti; Valerio Del Bono; Silvia Corcione; Giuseppe Maiuro; Sara Tedeschi; Luigi Celani; Chiara Simona Cardellino; Teresa Spanu; Anna Marchese; Simone Ambretti; Roberto Cauda; Claudio Viscoli; Pierluigi Viale
Journal:  J Antimicrob Chemother       Date:  2015-04-21       Impact factor: 5.790

4.  Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins.

Authors:  M S de Oliveira; D B de Assis; M P Freire; G V Boas do Prado; A S Machado; E Abdala; L C Pierrotti; C Mangini; L Campos; H H Caiaffa Filho; A S Levin
Journal:  Clin Microbiol Infect       Date:  2014-10-13       Impact factor: 8.067

5.  Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa.

Authors:  Neang S Ly; Zackery P Bulman; Jürgen B Bulitta; Christopher Baron; Gauri G Rao; Patricia N Holden; Jian Li; Mark D Sutton; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

6.  Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.

Authors:  T Tängdén; R A Hickman; P Forsberg; P Lagerbäck; C G Giske; O Cars
Journal:  Antimicrob Agents Chemother       Date:  2014-01-06       Impact factor: 5.191

7.  In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria.

Authors:  Elizabeth B Hirsch; Kimberly R Ledesma; Kai-Tai Chang; Michael S Schwartz; Mary R Motyl; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-04-23       Impact factor: 5.191

8.  Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.

Authors:  Brandon Kitchel; J Kamile Rasheed; Andrea Endimiani; Andrea M Hujer; Karen F Anderson; Robert A Bonomo; Jean B Patel
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

9.  Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model.

Authors:  George Michail; Maria Labrou; Vassiliki Pitiriga; Styliani Manousaka; Nikolaos Sakellaridis; Athanasios Tsakris; Spyros Pournaras
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

10.  Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA.

Authors:  Andrea Endimiani; Andrea M Hujer; Federico Perez; Christopher R Bethel; Kristine M Hujer; Jennifer Kroeger; Margret Oethinger; David L Paterson; Mark D Adams; Michael R Jacobs; Daniel J Diekema; Gerri S Hall; Stephen G Jenkins; Louis B Rice; Fred C Tenover; Robert A Bonomo
Journal:  J Antimicrob Chemother       Date:  2009-01-20       Impact factor: 5.790
View more
  8 in total

1.  In pursuit of the triple crown: mechanism-based pharmacodynamic modelling for the optimization of three-drug combinations against KPC-producing Klebsiella pneumoniae.

Authors:  N J Onufrak; N M Smith; M J Satlin; J B Bulitta; X Tan; P N Holden; R L Nation; J Li; A Forrest; B T Tsuji; Z P Bulman
Journal:  Clin Microbiol Infect       Date:  2020-05-05       Impact factor: 8.067

2.  Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B.

Authors:  Josiane F John; Diego R Falci; Maria Helena Rigatto; Renata D Oliveira; Thaysa G Kremer; Alexandre P Zavascki
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

3.  A coup d'état by NDM-producing Klebsiella pneumoniae overthrows the major bacterial population during KPC-directed therapy.

Authors:  Justin R Lenhard; Amisha P Rana; Eric Wenzler; Yanqin Huang; Barry N Kreiswirth; Liang Chen; Zackery P Bulman
Journal:  Diagn Microbiol Infect Dis       Date:  2020-05-15       Impact factor: 2.803

4.  International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).

Authors:  Brian T Tsuji; Jason M Pogue; Alexandre P Zavascki; Mical Paul; George L Daikos; Alan Forrest; Daniele R Giacobbe; Claudio Viscoli; Helen Giamarellou; Ilias Karaiskos; Donald Kaye; Johan W Mouton; Vincent H Tam; Visanu Thamlikitkul; Richard G Wunderink; Jian Li; Roger L Nation; Keith S Kaye
Journal:  Pharmacotherapy       Date:  2019-01       Impact factor: 6.251

5.  Combination antibiotic therapy for treatment of a patient with infected prosthesis and peri-prosthetic abscess due to Klebsiella pneumoniae harboring New Delhi Metallo (NDM) beta-lactamase.

Authors:  Monica Cespedes Santana; Ting Ting Wong; Carl Urban; Noriel Mariano; Janice Burns; George D Rodriguez; Elan Goldwyn; Nishant Prasad; Sorana Segal-Maurer
Journal:  IDCases       Date:  2022-01-06

6.  Experimental Validation of a Mathematical Framework to Simulate Antibiotics with Distinct Half-Lives Concurrently in an In Vitro Model.

Authors:  Brianna M Eales; Cole S Hudson; Iordanis Kesisoglou; Weiqun Wang; Michael Nikolaou; Vincent H Tam
Journal:  Antibiotics (Basel)       Date:  2021-10-16

7.  Combatting Planktonic and Biofilm Populations of Carbapenem-Resistant Acinetobacter baumannii with Polymyxin-Based Combinations.

Authors:  Marisol Wences; Elliot R Wolf; Cindy Li; Nidhi Singh; Nene Bah; Xing Tan; Yanqin Huang; Zackery P Bulman
Journal:  Antibiotics (Basel)       Date:  2022-07-16

8.  Bacterial Mixology: Combining Pharmacodynamic Models to Predict In Vitro Competition of MCR-1-Harboring E. coli.

Authors:  Nicholas M Smith; Arthur Chan; Thomas D Nguyen; Jacob T Dumbleton
Journal:  Antibiotics (Basel)       Date:  2021-12-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.